Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menadione is a synthetic lipid-soluble vitamin K analogue (vitamin K3) and a member of the 1,4-naphthoquinones. It acts as a provitamin that is converted in vivo to menaquinone (vitamin K2), an active form of vitamin K. Menadione serves as an essential cofactor in the hepatic synthesis of prothrombin (factor II) and other clotting factors (VII, IX, X), facilitating gamma-carboxylation necessary for blood coagulation. It has been used as a nutritional supplement and for treating hypoprothrombinemia due to vitamin K deficiency. Menadione also exhibits roles as an angiogenesis inhibitor and antineoplastic agent in research settings[1][2][3][7]. Its use in humans is limited due to potential toxicity at high doses; it remains approved primarily for veterinary use or animal feed supplementation[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on menadione.